How Chemotherapy Affects the Tumor Immune Microenvironment: A Narrative Review.
chemotherapy
immune cells
tumor microenvironment
Journal
Biomedicines
ISSN: 2227-9059
Titre abrégé: Biomedicines
Pays: Switzerland
ID NLM: 101691304
Informations de publication
Date de publication:
28 Jul 2022
28 Jul 2022
Historique:
received:
08
06
2022
revised:
23
07
2022
accepted:
25
07
2022
entrez:
26
8
2022
pubmed:
27
8
2022
medline:
27
8
2022
Statut:
epublish
Résumé
Chemotherapy is much more effective in immunocompetent mice than in immunodeficient ones, and it is now acknowledged that an efficient immune system is necessary to optimize chemotherapy activity and efficacy. Furthermore, chemotherapy itself may reinvigorate immune response in different ways: by targeting cancer cells through the induction of cell stress, the release of damage signals and the induction of immunogenic cell death, by targeting immune cells, inhibiting immune suppressive cells and/or activating immune effector cells; and by targeting the host physiology through changes in the balance of gut microbiome. All these effects acting on immune and non-immune components interfere with the tumor microenvironment, leading to the different activity and efficacy of treatments. This article describes the correlation between chemotherapy and the immune changes induced in the tumor microenvironment. Our ultimate aim is to pave the way for the identification of the best drugs or combinations, the doses, the schedules and the right sequences to use when chemotherapy is combined with immunotherapy.
Identifiants
pubmed: 36009369
pii: biomedicines10081822
doi: 10.3390/biomedicines10081822
pmc: PMC9405073
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
J Immunol. 2009 May 15;182(10):6562-8
pubmed: 19414811
Heliyon. 2018 Dec 18;4(12):e01039
pubmed: 30603685
Cancer Immunol Immunother. 2007 May;56(5):641-8
pubmed: 16960692
Oncoimmunology. 2013 Sep 1;2(9):e25962
pubmed: 24327938
Oncologist. 2016 Mar;21(3):283-91
pubmed: 26865589
Cancer Treat Rev. 2018 Feb;63:48-60
pubmed: 29223828
J Clin Oncol. 2005 Sep 10;23(26):6400-8
pubmed: 16155026
Cancer Cell. 2018 Jul 9;34(1):9-20
pubmed: 29731395
J Transl Med. 2016 Sep 29;14(1):282
pubmed: 27687804
Int J Mol Sci. 2019 May 26;20(10):
pubmed: 31130676
J Immunother Cancer. 2020 Mar;8(1):
pubmed: 32209603
Br J Cancer. 2014 Aug 12;111(4):646-50
pubmed: 24755886
J Cancer Res Clin Oncol. 2018 Jul;144(7):1219-1226
pubmed: 29675791
Br J Cancer. 2021 Oct;125(9):1197-1209
pubmed: 34262150
Eur J Cancer. 2019 Nov;121:123-129
pubmed: 31574417
J Immunother Cancer. 2022 Feb;10(2):
pubmed: 35135866
Eur J Immunol. 2013 Oct;43(10):2538-42
pubmed: 24122755
Sci Rep. 2018 Jan 17;8(1):914
pubmed: 29343810
Adv Skin Wound Care. 2009 Aug;22(8):353-5
pubmed: 19638797
Nat Rev Immunol. 2020 Feb;20(2):95-112
pubmed: 31558839
Oncology. 2010;79(3-4):187-96
pubmed: 21358206
Nature. 2001 Apr 19;410(6831):974-9
pubmed: 11309627
Ann Oncol. 2018 Jun 1;29(6):1437-1444
pubmed: 29617710
J Cell Physiol. 2019 Jun;234(6):7983-7993
pubmed: 30317612
J Transl Med. 2009 Jul 10;7:58
pubmed: 19591684
Oncol Lett. 2022 May;23(5):165
pubmed: 35414830
Nat Commun. 2018 Aug 24;9(1):3417
pubmed: 30143632
Vaccines (Basel). 2016 Nov 14;4(4):
pubmed: 27854240
Lancet Oncol. 2019 Feb;20(2):e77-e91
pubmed: 30712808
Cell Mol Immunol. 2021 May;18(5):1106-1121
pubmed: 33785842
Cancer Res. 2018 Oct 15;78(20):5891-5900
pubmed: 30104241
Nat Rev Cancer. 2017 May;17(5):286-301
pubmed: 28338065
Immunity. 2016 Mar 15;44(3):609-621
pubmed: 26944201
Head Neck. 2019 Mar;41(3):E42-E47
pubmed: 30614126
Immunity. 2013 Jul 25;39(1):74-88
pubmed: 23890065
Cancer Cell. 2013 Feb 11;23(2):249-62
pubmed: 23410977
Cancer Cell. 2018 Apr 9;33(4):570-580
pubmed: 29634945
NPJ Precis Oncol. 2022 Apr 20;6(1):26
pubmed: 35444175
Front Immunol. 2021 Feb 26;12:577766
pubmed: 33717062
Nat Rev Clin Oncol. 2017 Dec;14(12):717-734
pubmed: 28741618
Cell Death Differ. 2019 Jan;26(1):115-129
pubmed: 30341424
Anticancer Drugs. 2007 Jul;18(6):659-67
pubmed: 17762394
Immunotargets Ther. 2018 Jun 28;7:55-61
pubmed: 29988701
Nat Rev Microbiol. 2009 Feb;7(2):99-109
pubmed: 19148178
J Immunother Cancer. 2020 May;8(1):
pubmed: 32409420
Cancers (Basel). 2020 Sep 16;12(9):
pubmed: 32947882
Oncoimmunology. 2019 Apr 13;8(7):1596004
pubmed: 31143517
JCI Insight. 2019 Nov 14;4(22):
pubmed: 31600167
Eur J Cancer. 2020 Oct;138:149-155
pubmed: 32889369
BMC Cancer. 2019 Dec 23;19(1):1243
pubmed: 31870331
NAR Cancer. 2020 Feb 17;2(1):zcaa002
pubmed: 34316682
Nat Rev Cancer. 2016 Dec;16(12):759-773
pubmed: 27687979
Sci Adv. 2021 Oct 08;7(41):eabf6290
pubmed: 34613770
Future Oncol. 2020 Aug;16(24):1815-1824
pubmed: 32511016
Nat Rev Clin Oncol. 2010 Aug;7(8):455-65
pubmed: 20531380
Front Cell Dev Biol. 2020 Dec 18;8:619221
pubmed: 33392206
Science. 2018 Jan 5;359(6371):104-108
pubmed: 29302014
Cancer Cell. 2021 Mar 8;39(3):310-345
pubmed: 33338426
Eur J Immunol. 2014 Dec;44(12):3614-20
pubmed: 25251877
Cancer Res. 2017 Nov 15;77(22):6340-6352
pubmed: 28947417
Cell Death Differ. 2016 May;23(5):748-56
pubmed: 26915291
Cancer Immunol Immunother. 2017 Nov;66(11):1437-1447
pubmed: 28688082
Immunity. 2016 Feb 16;44(2):343-54
pubmed: 26872698
Cell Immunol. 2010;263(1):79-87
pubmed: 20346445
Curr Oncol Rep. 2016 Jul;18(7):42
pubmed: 27215436
JAMA Oncol. 2019 Dec 1;5(12):1774-1778
pubmed: 31513236
Nat Rev Immunol. 2010 Dec;10(12):826-37
pubmed: 21088683
J Thorac Oncol. 2018 Jan;13(1):106-111
pubmed: 29101058
Cancer Cell. 2015 Dec 14;28(6):690-714
pubmed: 26678337
Cell Rep. 2018 Mar 13;22(11):2978-2994
pubmed: 29539425
Cancer Res. 2009 Feb 15;69(4):1553-60
pubmed: 19201693
Science. 2018 Jan 5;359(6371):91-97
pubmed: 29097494
Cancer Lett. 2020 Nov 1;492:31-43
pubmed: 32758617
Cell Death Differ. 2014 Jan;21(1):15-25
pubmed: 23787994